Atrial fibrillation and use of rivaroxaban: performance of the prothrombin time/INR as a function of time after blood collection
Autor(a) principal: | |
---|---|
Data de Publicação: | 2020 |
Outros Autores: | , , , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional da UFMG |
Texto Completo: | https://doi.org/10.36660/ijcs.20190141 http://hdl.handle.net/1843/51569 https://orcid.org/0000-0002-4483-6489 https://orcid.org/0000-0003-1664-4946 https://orcid.org/0000-0003-4545-6821 https://orcid.org/0000-0001-5420-2482 https://orcid.org/0000-0003-3249-3711 https://orcid.org/0000-0003-4135-6161 https://orcid.org/0000-0002-9024-8872 https://orcid.org/0000-0002-7739-6440 https://orcid.org/0000-0003-1465-9167 https://orcid.org/0000-0002-1669-3302 https://orcid.org/0000-0002-4055-701X |
Resumo: | Background: Traditionally, the most effective therapy in the prevention of stroke in patients with atrial fibrillation (AF) has been oral anticoagulation with vitamin K inhibitors, particularly warfarin, whose disadvantages and adverse effects have led to their replacement by "direct oral anticoagulants", as factor X inhibitor. Objectives: This study aimed to conduct a brief approach on atrial fibrillation (AF) and use of Rivaroxaban, and to comparatively evaluate the prothrombin time / International Normalized Ratio (PT/INR) in patients with AF in use of this oral anticoagulant, depending on the time elapsed between the last administration of the drug and the time of blood sample venipuncture. Methods: We evaluated 34 patients with AF in use of Rivaroxaban by using PT / INR, distributed into a subgroup with blood collection time ≤ 12 hours (n = 7) and > 12 hours after the last drug intake (n = 27). Mann-Whitney test was used to compare the groups and p < 0.05 was considered significant. Results: An analysis as a function of time between the Rivaroxaban intake and blood collection, revealed that PT/INR suffers the greatest effect up to 12 hours after ingestion of the drug, dropping to levels close to normal in subsequent hours before the next dose. Conclusion: We concluded that, in contrast to warfarin, the knowledge of the time interval between drug intake and blood collection from patients taking Rivaroxaban is essential to properly interpret a laboratory test to assess hemostasis, particularly PT and its derivatives. |
id |
UFMG_1656aef95bc5a3ae9b7f009ab8e42573 |
---|---|
oai_identifier_str |
oai:repositorio.ufmg.br:1843/51569 |
network_acronym_str |
UFMG |
network_name_str |
Repositório Institucional da UFMG |
repository_id_str |
|
spelling |
2023-04-04T19:39:43Z2023-04-04T19:39:43Z2020-10-30342116121https://doi.org/10.36660/ijcs.201901412359-5647http://hdl.handle.net/1843/51569https://orcid.org/0000-0002-4483-6489https://orcid.org/0000-0003-1664-4946https://orcid.org/0000-0003-4545-6821https://orcid.org/0000-0001-5420-2482https://orcid.org/0000-0003-3249-3711https://orcid.org/0000-0003-4135-6161https://orcid.org/0000-0002-9024-8872https://orcid.org/0000-0002-7739-6440https://orcid.org/0000-0003-1465-9167https://orcid.org/0000-0002-1669-3302https://orcid.org/0000-0002-4055-701XBackground: Traditionally, the most effective therapy in the prevention of stroke in patients with atrial fibrillation (AF) has been oral anticoagulation with vitamin K inhibitors, particularly warfarin, whose disadvantages and adverse effects have led to their replacement by "direct oral anticoagulants", as factor X inhibitor. Objectives: This study aimed to conduct a brief approach on atrial fibrillation (AF) and use of Rivaroxaban, and to comparatively evaluate the prothrombin time / International Normalized Ratio (PT/INR) in patients with AF in use of this oral anticoagulant, depending on the time elapsed between the last administration of the drug and the time of blood sample venipuncture. Methods: We evaluated 34 patients with AF in use of Rivaroxaban by using PT / INR, distributed into a subgroup with blood collection time ≤ 12 hours (n = 7) and > 12 hours after the last drug intake (n = 27). Mann-Whitney test was used to compare the groups and p < 0.05 was considered significant. Results: An analysis as a function of time between the Rivaroxaban intake and blood collection, revealed that PT/INR suffers the greatest effect up to 12 hours after ingestion of the drug, dropping to levels close to normal in subsequent hours before the next dose. Conclusion: We concluded that, in contrast to warfarin, the knowledge of the time interval between drug intake and blood collection from patients taking Rivaroxaban is essential to properly interpret a laboratory test to assess hemostasis, particularly PT and its derivatives.Introdução: Tradicionalmente, a terapêutica mais eficaz na prevenção do AVC em doentes com fibrilhação auricular (FA) tem sido a anticoagulação oral com inibidores da vitamina K, nomeadamente a varfarina, cujas desvantagens e efeitos adversos têm levado à sua substituição por "anticoagulantes orais directos", como inibidor do fator X. Objetivos: Este estudo teve como objetivo fazer uma breve abordagem sobre fibrilação atrial (FA) e uso de Rivaroxabana, e avaliar comparativamente o tempo de protrombina/International Normalized Ratio (TP/INR) em pacientes com FA em uso desse anticoagulante oral, dependendo o tempo decorrido entre a última administração do medicamento e o momento da punção venosa da amostra de sangue. Métodos: Avaliamos 34 pacientes com FA em uso de Rivaroxabana por meio de TP/INR, distribuídos em um subgrupo com tempo de coleta de sangue ≤ 12 horas (n = 7) e > 12 horas após a última ingestão da droga (n = 27). O teste de Mann-Whitney foi usado para comparar os grupos e p < 0,05 foi considerado significativo. Resultados: A análise em função do tempo entre a ingestão de Rivaroxabana e a coleta de sangue revelou que a PT/INR sofre o maior efeito até 12 horas após a ingestão da droga, caindo para níveis próximos do normal nas horas subsequentes antes da próxima dose. Conclusão: Concluímos que, ao contrário da varfarina, o conhecimento do intervalo de tempo entre a ingestão do fármaco e a coleta de sangue de pacientes em uso de Rivaroxabana é fundamental para a correta interpretação de um exame laboratorial para avaliação da hemostasia, principalmente do TP e seus derivados.CNPq - Conselho Nacional de Desenvolvimento Científico e TecnológicoengUniversidade Federal de Minas GeraisUFMGBrasilCOLTEC - COLEGIO TECNICOFAR - DEPARTAMENTO DE ANÁLISES CLÍNICAS E TOXICOLÓGICASICB - DEPARTAMENTO DE FARMACOLOGIAICX - DEPARTAMENTO DE ESTATÍSTICAInternational Journal of Cardiovascular SciencesFibrilação atrialAcidente vascular cerebralEmboliaRivaroxabanaVarfarinaAnticoagulantesHemorragiaMedição de riscoCoagulação sanguíneaAtrial fibrillationStrokeEmbolismRivaroxabanWarfarinAnticoagulantsHemorrhage/physiopathologyRisk assessmentBlood coagulationAtrial fibrillation and use of rivaroxaban: performance of the prothrombin time/INR as a function of time after blood collectionFibrilação atrial e uso de rivaroxabana: desempenho do tempo de protrombina/INR em função do tempo após a coleta de sangueinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articlehttp://ijcscardiol.org/article/atrial-fibrillation-and-use-of-rivaroxaban-performance-of-the-prothrombin-time-inr-as-a-function-of-time-after-blood-collection/Rita Carolina Figueiredo DuartePriscila Samara Sérgio MoreiraCláudia Natália FerreiraEstevão Lanna FigueiredoEduardo SternickFrancisco Rezende SilveiraLuan Carlos Vieira AlvesAna Paula Lucas MotaEdna Afonso ReisMaria das Graças CarvalhoHelton José dos Reisapplication/pdfinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UFMGinstname:Universidade Federal de Minas Gerais (UFMG)instacron:UFMGLICENSELicense.txtLicense.txttext/plain; charset=utf-82042https://repositorio.ufmg.br/bitstream/1843/51569/1/License.txtfa505098d172de0bc8864fc1287ffe22MD51ORIGINALAtrial Fibrillation and Use of Rivaroxaban Performance of the Prothrombin Time INR as a Function of Time After Blood Collection.pdfAtrial Fibrillation and Use of Rivaroxaban Performance of the Prothrombin Time INR as a Function of Time After Blood Collection.pdfapplication/pdf281659https://repositorio.ufmg.br/bitstream/1843/51569/2/Atrial%20Fibrillation%20and%20Use%20of%20Rivaroxaban%20Performance%20of%20the%20Prothrombin%20Time%20INR%20as%20a%20Function%20of%20Time%20After%20Blood%20Collection.pdf030a35e28f3a4c1edde03bc0ed0ab9ffMD521843/515692023-04-04 16:39:43.282oai:repositorio.ufmg.br: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Repositório de PublicaçõesPUBhttps://repositorio.ufmg.br/oaiopendoar:2023-04-04T19:39:43Repositório Institucional da UFMG - Universidade Federal de Minas Gerais (UFMG)false |
dc.title.pt_BR.fl_str_mv |
Atrial fibrillation and use of rivaroxaban: performance of the prothrombin time/INR as a function of time after blood collection |
dc.title.alternative.pt_BR.fl_str_mv |
Fibrilação atrial e uso de rivaroxabana: desempenho do tempo de protrombina/INR em função do tempo após a coleta de sangue |
title |
Atrial fibrillation and use of rivaroxaban: performance of the prothrombin time/INR as a function of time after blood collection |
spellingShingle |
Atrial fibrillation and use of rivaroxaban: performance of the prothrombin time/INR as a function of time after blood collection Rita Carolina Figueiredo Duarte Atrial fibrillation Stroke Embolism Rivaroxaban Warfarin Anticoagulants Hemorrhage/physiopathology Risk assessment Blood coagulation Fibrilação atrial Acidente vascular cerebral Embolia Rivaroxabana Varfarina Anticoagulantes Hemorragia Medição de risco Coagulação sanguínea |
title_short |
Atrial fibrillation and use of rivaroxaban: performance of the prothrombin time/INR as a function of time after blood collection |
title_full |
Atrial fibrillation and use of rivaroxaban: performance of the prothrombin time/INR as a function of time after blood collection |
title_fullStr |
Atrial fibrillation and use of rivaroxaban: performance of the prothrombin time/INR as a function of time after blood collection |
title_full_unstemmed |
Atrial fibrillation and use of rivaroxaban: performance of the prothrombin time/INR as a function of time after blood collection |
title_sort |
Atrial fibrillation and use of rivaroxaban: performance of the prothrombin time/INR as a function of time after blood collection |
author |
Rita Carolina Figueiredo Duarte |
author_facet |
Rita Carolina Figueiredo Duarte Priscila Samara Sérgio Moreira Cláudia Natália Ferreira Estevão Lanna Figueiredo Eduardo Sternick Francisco Rezende Silveira Luan Carlos Vieira Alves Ana Paula Lucas Mota Edna Afonso Reis Maria das Graças Carvalho Helton José dos Reis |
author_role |
author |
author2 |
Priscila Samara Sérgio Moreira Cláudia Natália Ferreira Estevão Lanna Figueiredo Eduardo Sternick Francisco Rezende Silveira Luan Carlos Vieira Alves Ana Paula Lucas Mota Edna Afonso Reis Maria das Graças Carvalho Helton José dos Reis |
author2_role |
author author author author author author author author author author |
dc.contributor.author.fl_str_mv |
Rita Carolina Figueiredo Duarte Priscila Samara Sérgio Moreira Cláudia Natália Ferreira Estevão Lanna Figueiredo Eduardo Sternick Francisco Rezende Silveira Luan Carlos Vieira Alves Ana Paula Lucas Mota Edna Afonso Reis Maria das Graças Carvalho Helton José dos Reis |
dc.subject.por.fl_str_mv |
Atrial fibrillation Stroke Embolism Rivaroxaban Warfarin Anticoagulants Hemorrhage/physiopathology Risk assessment Blood coagulation |
topic |
Atrial fibrillation Stroke Embolism Rivaroxaban Warfarin Anticoagulants Hemorrhage/physiopathology Risk assessment Blood coagulation Fibrilação atrial Acidente vascular cerebral Embolia Rivaroxabana Varfarina Anticoagulantes Hemorragia Medição de risco Coagulação sanguínea |
dc.subject.other.pt_BR.fl_str_mv |
Fibrilação atrial Acidente vascular cerebral Embolia Rivaroxabana Varfarina Anticoagulantes Hemorragia Medição de risco Coagulação sanguínea |
description |
Background: Traditionally, the most effective therapy in the prevention of stroke in patients with atrial fibrillation (AF) has been oral anticoagulation with vitamin K inhibitors, particularly warfarin, whose disadvantages and adverse effects have led to their replacement by "direct oral anticoagulants", as factor X inhibitor. Objectives: This study aimed to conduct a brief approach on atrial fibrillation (AF) and use of Rivaroxaban, and to comparatively evaluate the prothrombin time / International Normalized Ratio (PT/INR) in patients with AF in use of this oral anticoagulant, depending on the time elapsed between the last administration of the drug and the time of blood sample venipuncture. Methods: We evaluated 34 patients with AF in use of Rivaroxaban by using PT / INR, distributed into a subgroup with blood collection time ≤ 12 hours (n = 7) and > 12 hours after the last drug intake (n = 27). Mann-Whitney test was used to compare the groups and p < 0.05 was considered significant. Results: An analysis as a function of time between the Rivaroxaban intake and blood collection, revealed that PT/INR suffers the greatest effect up to 12 hours after ingestion of the drug, dropping to levels close to normal in subsequent hours before the next dose. Conclusion: We concluded that, in contrast to warfarin, the knowledge of the time interval between drug intake and blood collection from patients taking Rivaroxaban is essential to properly interpret a laboratory test to assess hemostasis, particularly PT and its derivatives. |
publishDate |
2020 |
dc.date.issued.fl_str_mv |
2020-10-30 |
dc.date.accessioned.fl_str_mv |
2023-04-04T19:39:43Z |
dc.date.available.fl_str_mv |
2023-04-04T19:39:43Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/1843/51569 |
dc.identifier.doi.pt_BR.fl_str_mv |
https://doi.org/10.36660/ijcs.20190141 |
dc.identifier.issn.pt_BR.fl_str_mv |
2359-5647 |
dc.identifier.orcid.pt_BR.fl_str_mv |
https://orcid.org/0000-0002-4483-6489 https://orcid.org/0000-0003-1664-4946 https://orcid.org/0000-0003-4545-6821 https://orcid.org/0000-0001-5420-2482 https://orcid.org/0000-0003-3249-3711 https://orcid.org/0000-0003-4135-6161 https://orcid.org/0000-0002-9024-8872 https://orcid.org/0000-0002-7739-6440 https://orcid.org/0000-0003-1465-9167 https://orcid.org/0000-0002-1669-3302 https://orcid.org/0000-0002-4055-701X |
url |
https://doi.org/10.36660/ijcs.20190141 http://hdl.handle.net/1843/51569 https://orcid.org/0000-0002-4483-6489 https://orcid.org/0000-0003-1664-4946 https://orcid.org/0000-0003-4545-6821 https://orcid.org/0000-0001-5420-2482 https://orcid.org/0000-0003-3249-3711 https://orcid.org/0000-0003-4135-6161 https://orcid.org/0000-0002-9024-8872 https://orcid.org/0000-0002-7739-6440 https://orcid.org/0000-0003-1465-9167 https://orcid.org/0000-0002-1669-3302 https://orcid.org/0000-0002-4055-701X |
identifier_str_mv |
2359-5647 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.ispartof.pt_BR.fl_str_mv |
International Journal of Cardiovascular Sciences |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Universidade Federal de Minas Gerais |
dc.publisher.initials.fl_str_mv |
UFMG |
dc.publisher.country.fl_str_mv |
Brasil |
dc.publisher.department.fl_str_mv |
COLTEC - COLEGIO TECNICO FAR - DEPARTAMENTO DE ANÁLISES CLÍNICAS E TOXICOLÓGICAS ICB - DEPARTAMENTO DE FARMACOLOGIA ICX - DEPARTAMENTO DE ESTATÍSTICA |
publisher.none.fl_str_mv |
Universidade Federal de Minas Gerais |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da UFMG instname:Universidade Federal de Minas Gerais (UFMG) instacron:UFMG |
instname_str |
Universidade Federal de Minas Gerais (UFMG) |
instacron_str |
UFMG |
institution |
UFMG |
reponame_str |
Repositório Institucional da UFMG |
collection |
Repositório Institucional da UFMG |
bitstream.url.fl_str_mv |
https://repositorio.ufmg.br/bitstream/1843/51569/1/License.txt https://repositorio.ufmg.br/bitstream/1843/51569/2/Atrial%20Fibrillation%20and%20Use%20of%20Rivaroxaban%20Performance%20of%20the%20Prothrombin%20Time%20INR%20as%20a%20Function%20of%20Time%20After%20Blood%20Collection.pdf |
bitstream.checksum.fl_str_mv |
fa505098d172de0bc8864fc1287ffe22 030a35e28f3a4c1edde03bc0ed0ab9ff |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 |
repository.name.fl_str_mv |
Repositório Institucional da UFMG - Universidade Federal de Minas Gerais (UFMG) |
repository.mail.fl_str_mv |
|
_version_ |
1803581630284038144 |